



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
PTO-1449**

ATTY. DOCKET NO.
1662/61403

SERIAL NO.
10/688,538

APPLICANT
Ben-Zion DOLITZKY et al.

FILING DATE
October 16, 2003

GROUP
Not Yet Assigned

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLAS S	SUBCLAS S	FILING DATE*
<i>MB</i>	*4,957,924	Sept. 18, 1990	Beauchamp			
<i>MB</i>	*5,879,706	Mar. 9, 1999	Carter et al			
<i>MB</i>	*6,107,302	Aug. 22, 2000	Carter et al.			

* A copy is not enclosed since this application was filed after June 30, 2003.

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA- TION	
						YES	NO
<i>MB</i>	WO 03/041647 A2	May 22, 2003	PCT				
<i>MB</i>	WO 03/041647 A3	Nov. 20, 2003	PCT				
<i>MB</i>	0 665 229 A1	August 2, 1995	Europe				

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
<i>MB</i>	Goodman and Gilman, The Pharmacological Basis of Therapeutics, 9 th Ed., 1996, pp. 13 and 1193-1198
<i>MB</i>	International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use; Impurities: Guideline for Residual Solvents Q3C, Step 4 of the ICH Process, July 17, 1997, pp 1-16

EXAMINER	<i>Mark Ben</i>	DATE CONSIDERED	9/21/05
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			